NGS Newborn Genetic Testing/Screening Market

Global NGS Newborn Genetic Testing/Screening Market Size, Trends & Analysis - Forecasts to 2027 By Application (Inherited & Other Screening/Testing Disorders and Pharmacogenomics), By Sample Type (Blood, Saliva, and Others), By End-Use (Hospitals & Clinics, Diagnostic Centers, and Others), By Region (North America, Asia Pacific, CSA, Europe, and the Middle East and Africa), Company Market Share Analysis, and Competitor Analysis

Category Healthcare

Format

This report was recently updated on December 17 2024 with the latest and most recent market numbers

NGS Newborn Genetic Testing/Screening Market Size

The Global NGS Newborn Genetic Testing/Screening Market is projected to grow at a CAGR value of 12.7% between 2022 to 2027. The incidence of acquired diseases and genetic disorders among newborns has played a crucial role in the development of novel newborn testing methods.

Advancements in the field of Next-Generation Sequencing technology have led to the development of novel newborn testing procedures in recent years. The development of these testing techniques allows for the non-invasive screening of newborns within 24 hours of their birth.

The growing incidence of genetic disorders among the population has been a major driver of the market. Increasing demand for newborn testing/screening procedures to identify genetic defects as early as possible has been crucial to the development of the market.

The risk of increased fatality and other complications due to delayed diagnosis can have long-term irreparable consequences for the child. It is estimated that at least 65% of the population has some form of health issue stemming from congenital genetic mutations.

The growing number of collaborations between pharmaceutical companies and research institutions in developing novel newborn testing procedures have impacted the market positively. The growing number of newborns and high population increase in developing regions are expected to further enhance the growth of the NGS newborn genetic testing/screening market.

Early diagnosis and newborn testing have been growing in demand owing to the growing instances of stillbirths and neonatal fatalities across the globe. As per the estimates of the Indian Pediatric Academy, 9 out of every 1,000 births in India suffer from some form of congenital heart disease. The high birth rate in India has led to over 200,000 children being born with congenital heart diseases. Meanwhile, in the United States, the number of newborns with congenital heart disease per 1,000 births has been estimated to be two. The stark difference between the incidence of genetic disorders in newborns in developed and developing countries is estimated to offer lucrative opportunities in developing regions across the globe.

Growing investment in healthcare facilities across the globe has increased access to new and revolutionary technologies. The development of Next-Generation Sequencing diagnostics has been heavily monitored by most healthcare providers. Increasing the adoption of NGS in various diagnostic techniques will increase the availability of these diagnostic services during the forecast period. With many unmet diagnostic needs for efficient newborn testing/screening, developments in NGS newborn screening/testing will have many opportunities for growth during the forecast period.

Despite the rapid rise of NGS tests, a number of major concerns will need to be addressed in order to support future growth. The high cost of NGS procedures and lack of adequate and affordable insurance coverage will hinder the growth of the market.

The COVID-19 pandemic had led to hospitals being understaffed as healthcare facilities struggled to maintain an adequate workforce. Increased demand for healthcare facilities combined with healthcare workers battling COVID infections themselves led to hospitals reducing patient intake. Many optional procedures and non-threatening diagnoses and treatments were pushed back. The heavy investment in healthcare facilities during the pandemic is expected to have a positive impact on the NGS newborn genetic testing/screening market.

The NGS newborn genetic testing/screening market is driven mainly by the growing incidence of genetic disorders, the increasing adoption of NGS diagnostics, the growing incidence of newborn fatalities, and the rising investment in newborn testing facilities.

global ngs newborn genetic testing/screening market

NGS Newborn Genetic Testing/Screening Market: By Application

Based on the application, the NGS newborn genetic testing/screening market is segmented into inherited & other screening/testing disorders and pharmacogenomics. The inherited & other screening/testing disorders segment is expected to hold the most significant piece of the market during the forecast period.

The inherited & other screening/testing disorders segment has been primarily driven by the growing number of genetic disorders. Increasing investment in developing new testing/screening procedures based on NGS is expected to result in the segment becoming the fastest-growing segment.

NGS Newborn Genetic Testing/Screening Market: By Sample Type

Based on the various sample types in the NGS newborn genetic testing/screening market, the market is segmented into blood, saliva, and others. The blood segment held the lion's share of the market. The growing demand for non-invasive testing procedures and the increasing investment in the development of new diagnostic procedures are expected to result in the saliva segment becoming the fastest-growing segment during the forecast period.

NGS Newborn Genetic Testing/Screening Market: By End-User

Based on the various end-users, the market is segmented into hospitals & clinics, diagnostic centers, and others. The hospitals & clinics segment held the lion's share of the market.

asia pacific ngs newborn genetic testing/screening market

NGS Newborn Genetic Testing/Screening Market: By Region

Based on region, the market can be segmented into various regions such as North America, Europe, Central and South America, the Middle East and North Africa, and Asia Pacific regions.

The North American region is expected to be the dominant force in the market during the forecast period. The heavy investment in healthcare facilities, advanced insurance coverage, and greater adoption of new diagnostic procedures in the region have contributed to the dominance of the North American region in the NGS newborn genetic testing/screening market.

The APAC region is anticipated to become the fastest-growing region. The increasing birth rate and growing prevalence of genetic disorders among the population are expected to result in the rapid development of the NGS newborn testing/screening market in the APAC region.

NGS Newborn Genetic Testing/Screening Market Share and Competitor Analysis

LifeCell International Pvt. Ltd., BGI, PerkinElmer Genomics, CENTOGENE N.V., CryoCell International, Fulgent Genetics., Igenomix, Veritas Intercontinental, GENEPATH, and MedGenome, among others, are the key players in the NGS newborn genetic testing/screening market.

Please note: This is not an exhaustive list of companies profiled in the report.

Chapter 1 Methodology

1.1 Market Scope & Definitions

1.2 Estimates & Forecast Calculation

1.3 Historical Data Overview and Validation

1.4 Data Sources

1.4.1 Secondary

1.4.2 Primary

Chapter 2 Report Outlook

2.1 NGS Newborn Genetic Testing/Screening Industry Overview, 2020-2026

2.1.1 Industry Overview

2.1.2 Application Overview

2.1.3 Sample Type Overview

2.1.4 End-User Overview

2.1.6 Regional Overview

Chapter 3 NGS Newborn Genetic Testing/Screening Market Trends

3.1 Market Segmentation

3.2 Industry Background, 2020-2026

3.3 Market Key Trends

3.3.1 Positive Trends

3.3.1.1 Rising prevalence of genetic disorders

3.3.2 Industry Challenges

3.3.2.1 High cost of development and stringent regulations

3.4 Prospective Growth Scenario

3.4.1 Application Growth Scenario

3.4.2 Sample Type Growth Scenario

3.4.3 End-User Growth Scenario

3.5 COVID-19 Influence over Industry Growth

3.6 Porter’s Analysis

3.7 PESTEL Analysis

3.8 Value Chain & Supply Chain Analysis

3.9 Regulatory Framework

3.9.1 North America

3.9.2 Europe

3.9.3 APAC

3.9.4 LATAM

3.9.5 MEA

3.10 End-User Overview

3.11 Market Share Analysis, 2020

3.11.1 Company Positioning Overview, 2020

Chapter 4 NGS Newborn Genetic Testing/Screening Market, By Application

4.1 Application Outlook

4.2 Inherited & Other Disorders Screening/ Testing

4.2.1 Market Size, By Region, 2020-2026 (USD Million)

4.3 Pharmacogenomics

4.3.1 Market Size, By Region, 2020-2026 (USD Million)

Chapter 5 NGS Newborn Genetic Testing/Screening Market, By Sample Type

5.1 Sample Type Outlook

5.2 Blood

5.2.1 Market Size, By Region, 2020-2026 (USD Million)

5.3 Saliva

5.3.1 Market Size, By Region, 2020-2026 (USD Million)

5.4 Others

5.4.1 Market Size, By Region, 2020-2026 (USD Million)

Chapter 6 NGS Newborn Genetic Testing/Screening Market, By End-User

6.1 Hospitals & Clinics

6.1.1 Market Size, By Region, 2020-2026 (USD Million)

6.2 Diagnostic Centers

6.2.1 Market Size, By Region, 2020-2026 (USD Million)

6.3 Others

6.3.1 Market Size, By Region, 2020-2026 (USD Million)

Chapter 7 NGS Newborn Genetic Testing/Screening Market, By Region

7.1 Regional outlook

7.2 North America

7.2.1 Market Size, By Country 2020-2026 (USD Million)

7.2.2 Market Size, By Application, 2020-2026 (USD Million)

7.2.3 Market Size, By Sample Type, 2020-2026 (USD Million)

7.2.4 Market Size, By End-User, 2020-2026 (USD Million)

7.2.6 U.S.

7.2.6.1 Market Size, By Application, 2020-2026 (USD Million)

7.2.4.2 Market Size, By Sample Type, 2020-2026 (USD Million)

7.2.4.3 Market Size, By End-User, 2020-2026 (USD Million)

7.2.7 Canada

7.2.7.1 Market Size, By Application, 2020-2026 (USD Million)

7.2.7.2 Market Size, By Sample Type, 2020-2026 (USD Million)

7.2.7.3 Market Size, By End-User, 2020-2026 (USD Million)

7.3 Europe

7.3.1 Market Size, By Country 2020-2026 (USD Million)

7.3.2 Market Size, By Application, 2020-2026 (USD Million)

7.3.3 Market Size, By Sample Type, 2020-2026 (USD Million)

7.3.4 Market Size, By End-User, 2020-2026 (USD Million)

7.3.6 Germany

7.3.6.1 Market Size, By Application, 2020-2026 (USD Million)

7.3.6.2 Market Size, By Sample Type, 2020-2026 (USD Million)

7.3.6.3 Market Size, By End-User, 2020-2026 (USD Million)

7.3.7 UK

7.3.7.1 Market Size, By Application, 2020-2026 (USD Million)

7.3.7.2 Market Size, By Sample Type, 2020-2026 (USD Million)

7.3.7.3 Market Size, By End-User, 2020-2026 (USD Million)

7.3.8 France

7.3.7.1 Market Size, By Application, 2020-2026 (USD Million)

7.3.7.2 Market Size, By Sample Type, 2020-2026 (USD Million)

7.3.7.3 Market Size, By End-User, 2020-2026 (USD Million)

7.3.9 Italy

7.3.9.1 Market Size, By Application, 2020-2026 (USD Million)

7.3.9.2 Market Size, By Sample Type, 2020-2026 (USD Million)

7.3.9.3 Market Size, By End-User, 2020-2026 (USD Million)

7.3.10 Spain

7.3.10.1 Market Size, By Application, 2020-2026 (USD Million)

7.3.10.2 Market Size, By Sample Type, 2020-2026 (USD Million)

7.3.10.3 Market Size, By End-User, 2020-2026 (USD Million)

7.3.11 Russia

7.3.11.1 Market Size, By Application, 2020-2026 (USD Million)

7.3.11.2 Market Size, By Sample Type, 2020-2026 (USD Million)

7.3.11.3 Market Size, By End-User, 2020-2026 (USD Million)

7.4 Asia Pacific

7.4.1 Market Size, By Country 2020-2026 (USD Million)

7.4.2 Market Size, By Application, 2020-2026 (USD Million)

7.4.3 Market Size, By Sample Type, 2020-2026 (USD Million)

7.4.4 Market Size, By End-User, 2020-2026 (USD Million)

7.4.6 China

7.4.6.1 Market Size, By Application, 2020-2026 (USD Million)

7.4.6.2 Market Size, By Sample Type, 2020-2026 (USD Million)

7.4.6.3 Market Size, By End-User, 2020-2026 (USD Million)

7.4.7 India

7.4.7.1 Market Size, By Application, 2020-2026 (USD Million)

7.4.7.2 Market Size, By Sample Type, 2020-2026 (USD Million)

7.4.7.3 Market Size, By End-User, 2020-2026 (USD Million)

7.4.8 Japan

7.4.7.1 Market Size, By Application, 2020-2026 (USD Million)

7.4.7.2 Market Size, By Sample Type, 2020-2026 (USD Million)

7.4.7.3 Market Size, By End-User, 2020-2026 (USD Million)

7.4.9 Australia

7.4.9.1 Market Size, By Application, 2020-2026 (USD Million)

7.4.9.2 Market size, By Sample Type, 2020-2026 (USD Million)

7.4.9.3 Market Size, By End-User, 2020-2026 (USD Million)

7.4.10 South Korea

7.4.10.1 Market Size, By Application, 2020-2026 (USD Million)

7.4.10.2 Market Size, By Sample Type, 2020-2026 (USD Million)

7.4.10.3 Market Size, By End-User, 2020-2026 (USD Million)

7.5 Latin America

7.5.1 Market Size, By Country 2020-2026 (USD Million)

7.5.2 Market Size, By Application, 2020-2026 (USD Million)

7.5.3 Market Size, By Sample Type, 2020-2026 (USD Million)

7.5.4 Market Size, By End-User, 2020-2026 (USD Million)

7.5.6 Brazil

7.5.6.1 Market Size, By Application, 2020-2026 (USD Million)

7.5.6.2 Market Size, By Sample Type, 2020-2026 (USD Million)

7.5.6.3 Market Size, By End-User, 2020-2026 (USD Million)

7.5.7 Mexico

7.5.7.1 Market Size, By Application, 2020-2026 (USD Million)

7.5.7.2 Market Size, By Sample Type, 2020-2026 (USD Million)

7.5.7.3 Market Size, By End-User, 2020-2026 (USD Million)

7.5.8 Argentina

7.5.7.1 Market Size, By Application, 2020-2026 (USD Million)

7.5.7.2 Market Size, By Sample Type, 2020-2026 (USD Million)

7.5.7.3 Market Size, By End-User, 2020-2026 (USD Million)

7.6 MEA

7.6.1 Market Size, By Country 2020-2026 (USD Million)

7.6.2 Market Size, By Application, 2020-2026 (USD Million)

7.6.3 Market Size, By Sample Type, 2020-2026 (USD Million)

7.6.4 Market Size, By End-User, 2020-2026 (USD Million)

7.6.6 Saudi Arabia

7.6.6.1 Market Size, By Application, 2020-2026 (USD Million)

7.6.6.2 Market Size, By Sample Type, 2020-2026 (USD Million)

7.6.6.3 Market Size, By End-User, 2020-2026 (USD Million)

7.6.7 UAE

7.6.7.1 Market Size, By Application, 2020-2026 (USD Million)

7.6.7.2 Market Size, By Sample Type, 2020-2026 (USD Million)

7.6.7.3 Market Size, By End-User, 2020-2026 (USD Million)

7.6.8 South Africa

7.6.7.1 Market Size, By Application, 2020-2026 (USD Million)

7.6.7.2 Market Size, By Sample Type, 2020-2026 (USD Million)

7.6.7.3 Market Size, By End-User, 2020-2026 (USD Million)

Chapter 8 Company Landscape

8.1 Competitive Analysis, 2020

8.2 LifeCell International Pvt. Ltd

8.2.1 Company Overview

8.2.2 Financial Analysis

8.2.3 Strategic Positioning

8.2.4 Info Graphic Analysis

8.3 BGI

8.3.1 Company Overview

8.3.2 Financial Analysis

8.3.3 Strategic Positioning

8.3.4 Info Graphic Analysis

8.4 PerkinElmer Genomics

8.4.1 Company Overview

8.4.2 Financial Analysis

8.4.3 Strategic Positioning

8.4.4 Info Graphic Analysis

8.5 CENTOGENE N.V.

8.5.1 Company Overview

8.5.2 Financial Analysis

8.5.3 Strategic Positioning

8.5.4 Info Graphic Analysis

8.6 CryoCell International

8.6.1 Company Overview

8.6.2 Financial Analysis

8.6.3 Strategic Positioning

8.6.4 Info Graphic Analysis

8.7 Fulgent Genetics

8.7.1 Company Overview

8.7.2 Financial Analysis

8.7.3 Strategic Positioning

8.7.4 Info Graphic Analysis

8.8 Igenomix

8.8.1 Company Overview

8.8.2 Financial Analysis

8.8.3 Strategic Positioning

8.8.4 Info Graphic Analysis

8.9 Veritas Intercontinental

8.8.1 Company Overview

8.8.2 Financial Analysis

8.8.3 Strategic Positioning

8.8.4 Info Graphic Analysis

8.10 GENEPATH

8.10.1 Company Overview

8.10.2 Financial Analysis

8.10.3 Strategic Positioning

8.10.4 Info Graphic Analysis

8.11 Other Companies

8.11.1 Company Overview

8.11.2 Financial Analysis

8.11.3 Strategic Positioning

8.11.4 Info Graphic Analysis

The Global NGS Newborn Genetic Testing/Screening Market has been studied from the year 2019 till 2027. However, the CAGR provided in the report is from the year 2022 to 2027. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.

The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the NGS Newborn Genetic Testing/Screening Market.

The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.

Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.

We value your investment and offer free customization with every report to fulfil your exact research needs.

This website is secure and your personal details are safe. Privacy

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

What is the projected market size of the global NGS newborn genetic testing/screening market?

The global NGS newborn genetic testing/screening market size is projected to grow at a CAGR value of 12.7% between 2022 and 2027.

Who are the major vendors in the NGS newborn genetic testing/screening market?

Key and innovative vendors in the NGS newborn genetic testing/screening market include LifeCell International Pvt. Ltd., BGI, PerkinElmer Genomics, CENTOGENE N.V., CryoCell International, Fulgent Genetics., Igenomix, Veritas Intercontinental, GENEPATH, and MedGenome, among others.

Which region has the highest market share in the NGS newborn genetic testing/screening market?

The North American region is estimated to hold the largest share of the NGS newborn genetic testing/screening market.

What is the Covid-19 impact on future NGS newborn genetic testing/screening manufacturers?

What are the major drivers in the NGS newborn genetic testing/screening market?